IRWD

Ironwood Pharmaceuticals, Inc. [IRWD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IRWD Stock Summary

Top IRWD Correlated Resources

IRWD


Top 10 Correlated ETFs

IRWD


Top 10 Correlated Stocks

IRWD


In the News

07:30 26 Feb 2024 IRWD

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference. ASPEN is being held from March 2-5, 2024,.

10:41 26 Feb 2024 IRWD

Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally

Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.

09:16 26 Feb 2024 IRWD

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4

Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.20. This compares to earnings of $0.27 per share a year ago.

09:51 26 Feb 2024 IRWD

Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

04:01 26 Feb 2024 IRWD

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (647) 495-7514 (international) using conference ID number and event passcode 1057375. To access the webcast, please visit the Investors section of Ironwood's w.

10:56 26 Feb 2024 IRWD

Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet

The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

04:01 26 Feb 2024 IRWD

Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time at The Westin St. Francis in San Francisco, CA. A live audio webcast of Ironwood's presentation will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. To access.

12:47 26 Feb 2024 IRWD

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

10:39 26 Feb 2024 IRWD

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities David Amsellem - Piper Sandler Boris Peaker - TD Cowen Tim Chiang - Capital One Operator Thank you for standing by. My name is Aaron, and I will be your conference operator for today.

04:13 26 Feb 2024 IRWD

Ironwood Pharmaceuticals: The Right Play Now

Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently acquired VectivBio and its drug candidate apraglutide, which is undergoing evaluation for the treatment of short bowel syndrome with intestinal failure.

IRWD Financial details

Company Rating
Neutral
Market Cap
2.36B
Income
-938.69M
Revenue
442.74M
Book val./share
-2.09
Cash/share
0.71
Dividend
-
Dividend %
-
Employees
267
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.05
Forward P/E
15.7
PEG
0.03
P/S
4.52
P/B
-5.99
P/C
21.23
P/FCF
8.61
Quick Ratio
0.84
Current Ratio
0.9
Debt / Equity
-2.27
LT Debt / Equity
-
-
-
EPS (TTM)
-6.45
EPS next Y
0.96
EPS next Q
1.57
EPS this Y
-670.8%
EPS next Y
-114.83%
EPS next 5Y
-114.83%
EPS last 5Y
130.93%
Revenue last 5Y
0.66%
Revenue Q/Q
3.35%
EPS Q/Q
-110%
-
-
-
-
SMA20
16.94%
SMA50
46.12%
SMA100
59.77%
Inst Own
76.45%
Inst Trans
0.72%
ROA
-182%
ROE
-555%
ROC
-3.76%
Gross Margin
100%
Oper. Margin
-212%
Profit Margin
-220%
Payout
-
Shs Outstand
156.53M
Shs Float
152.14M
-
-
-
-
Target Price
16
52W Range
8.07-15.7
52W High
+0.47%
52W Low
+88.38%
RSI
62.9
Rel Volume
0.51
Avg Volume
2.93M
Volume
1.49M
Perf Week
-0.86%
Perf Month
21.14%
Perf Quarter
71.25%
Perf Half Y
64.7%
-
-
-
-
Beta
0.626
-
-
Volatility
0.25%, 1.12%
Prev Close
1.41%
Price
15.07
Change
-0.59%

IRWD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
2.272.752.442.552.66
Net income per share
-1.85-0.10.673.261.13
Operating cash flow per share
-0.460.071.061.611.77
Free cash flow per share
-0.520.021.051.611.77
Cash per share
1.131.132.273.824.25
Book value per share
-1.29-0.60.393.734.23
Tangible book value per share
-1.29-0.60.393.734.23
Share holders equity per share
-1.29-0.60.393.734.23
Interest debt per share
2.9433.033.122.74
Market cap
1.58B2.08B1.82B1.89B1.91B
Enterprise value
1.82B2.33B1.91B1.75B1.67B
P/E ratio
-5.6-135.6117.13.5810.93
Price to sales ratio
4.564.854.664.574.66
POCF ratio
-22.31193.6310.767.226.99
PFCF ratio
-19.89587.2910.877.236.99
P/B Ratio
-8.05-22.2728.993.122.93
PTB ratio
-8.05-22.2728.993.122.93
EV to sales
5.265.444.94.224.07
Enterprise value over EBITDA
-19.419.3611.937.56.44
EV to operating cash flow
-25.71217.3311.36.676.11
EV to free cash flow
-22.92659.1811.426.686.11
Earnings yield
-0.18-0.010.060.280.09
Free cash flow yield
-0.0500.090.140.14
Debt to equity
-2.11-4.627.240.790.64
Debt to assets
1.251.070.810.420.38
Net debt to EBITDA
-2.562.110.57-0.62-0.92
Current ratio
2.237.515.164.6130.58
Interest coverage
-6.883.284.857.4632.95
Income quality
0.250.51.590.51.56
Dividend Yield
00000.06
Payout ratio
00000.63
Sales general and administrative to revenue
0.70000
Research and developement to revenue
0.480.270.230.170.11
Intangibles to total assets
00000
Capex to operating cash flow
0.12-0.67-0.0100
Capex to revenue
-0.02-0.02000
Capex to depreciation
-0.61-1.29-0.52-0.17-0.1
Stock based compensation to revenue
0.130.070.080.050.07
Graham number
7.321.152.4316.5410.38
ROIC
-1.07-0.090.260.550.16
Return on tangible assets
-0.85-0.040.190.470.16
Graham Net
-1.93-1.48-0.271.141.91
Working capital
146.91M265.92M463.13M583.53M755.1M
Tangible asset value
-197.16M-94.04M61.86M605.91M652.38M
Net current asset value
-261.99M-189.15M-759K224.21M332.49M
Invested capital
-2.11-4.627.240.790.64
Average receivables
81.55M99.1M119.8M118.2M114.75M
Average payables
66.55M38.54M3.07M798K709K
Average inventory
367.5K324K324K0625K
Days sales outstanding
85.2499.89114.65100.6102.64
Days payables outstanding
797.8983.8976.9300
Days of inventory on hand
09.91000
Receivables turnover
4.283.653.183.633.56
Payables turnover
0.464.354.7400
Inventory turnover
036.84000
ROE
1.440.161.70.870.27
Capex per share
-0.06-0.05-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.710.70.670.690.73
Net income per share
0.330.320.3-6.840.1
Operating cash flow per share
0.450.520.520.230.21
Free cash flow per share
0.450.520.520.230.21
Cash per share
3.754.284.791.130.71
Book value per share
3.864.254.58-2.23-2.09
Tangible book value per share
3.864.254.58-2.26-2.11
Share holders equity per share
3.864.254.58-2.23-2.09
Interest debt per share
2.732.722.75.264.81
Market cap
1.59B1.9B1.62B1.65B1.5B
Enterprise value
1.43B1.66B1.3B2.29B2.13B
P/E ratio
7.889.728.89-0.3924.5
Price to sales ratio
14.617.7215.6115.3913.2
POCF ratio
22.9523.9920.2747.2846.25
PFCF ratio
22.9723.9920.2747.2846.32
P/B Ratio
2.682.912.3-4.77-4.61
PTB ratio
2.682.912.3-4.77-4.61
EV to sales
13.1415.4812.521.3618.74
Enterprise value over EBITDA
20.0422.4819.3-2.1645.89
EV to operating cash flow
20.6620.9616.2265.665.67
EV to free cash flow
20.6820.9516.2265.665.77
Earnings yield
0.030.030.03-0.640.01
Free cash flow yield
0.040.040.050.020.02
Debt to equity
0.70.640.59-2.35-2.27
Debt to assets
0.40.380.361.351.41
Net debt to EBITDA
-2.22-3.26-4.82-0.613.57
Current ratio
25.7830.5836.341.040.9
Interest coverage
60.8644.839.36-588.664.07
Income quality
1.371.621.75-0.032.33
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.110.10.1210.480.29
Intangibles to total assets
0000.010.01
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.180.08-0.050-0.1
Stock based compensation to revenue
0.070.070.070.080.07
Graham number
5.345.525.5218.532.15
ROIC
0.050.040.04-2.250.04
Return on tangible assets
0.050.040.04-1.770.03
Graham Net
1.391.932.46-4.41-4.14
Working capital
671.88M755.1M842.53M12.21M-26.97M
Tangible asset value
591.06M652.38M706.85M-350.87M-329.57M
Net current asset value
249.71M332.49M417.95M-632.4M-596.13M
Invested capital
0.70.640.59-2.35-2.27
Average receivables
109.45M116M115.6M117.37M121.77M
Average payables
556K639K300.5K1.81M4.1M
Average inventory
0625K1.25M1.02M788K
Days sales outstanding
96.5596.93100.1199.7398.55
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.930.930.90.90.91
Payables turnover
00000
Inventory turnover
00000
ROE
0.090.070.063.06-0.05
Capex per share
00000

IRWD Frequently Asked Questions

What is Ironwood Pharmaceuticals, Inc. stock symbol ?

Ironwood Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol IRWD

Is Ironwood Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $16. The lowest prediction is $16 and the highest is $16

What is IRWD stock prediction ?

What is Ironwood Pharmaceuticals, Inc. stock quote today ?

Ironwood Pharmaceuticals, Inc. stock price is $15.07 today.

Is Ironwood Pharmaceuticals, Inc. stock public?

Yes, Ironwood Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap